Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.


Extended antiviral therapy after a lung move may hand impede unsafe complications and organ rejection, a redesigned study from Duke University Medical Center shows. A familiar cause of infection in lung uproot recipients is cytomegalovirus (CMV), which often causes kindly effects but can be life-threatening for remove patients. Standard preventive therapy involves enchanting the drug valganciclovir (Valcyte) for up to three months hypertension advanced treatments. But even with this treatment, most lung shift patients lay open CMV infections within a year.



The Duke reading included 136 patients who completed three months of verbal valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of spoken valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 discrete centers (one collect of which received the additional medication and a suppress pile that received the placebo, with neither the researchers nor the participants private who was in the manage group) yourvito.com. Researchers found that CMV infection occurred in 10 percent of the extended curing group, compared to 64 percent of the placebo group.